© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cisapride’s story traces back to the days when gastrintestinal motility disorders lacked truly effective medical answers. Researchers started with compounds related to serotonin, since gut function responded to chemical messengers. Through years of lab work in the 1980s, cisapride came out as a standout for stimulating gut muscle contractions. Approval came fast because chronic heartburn and delayed gastric emptying conditions affected so many lives. For a while, patients and doctors cheered its results, as cisapride relieved tough cases of acid reflux and gastroparesis, especially for those where prior medicines just didn’t work.
Cisapride works by enhancing acetylcholine release in the gut, improving muscle movement and speeding up how quickly the stomach empties. Markets offered it under names like Prepulsid, Propulsid, and others. Usually, the drug came as tablets or liquid, with strengths tailored for adults and children struggling with sluggish digestive tracts. Hospitals, community clinics, and pharmacies relied on its effects to help manage unyielding symptoms when antacids or lifestyle changes gave only partial relief.
Cisapride appears as a white to slightly off-white powder. It can dissolve in methanol and ethanol, but barely budges in water, which nudged chemists to create salts to improve oral absorption. Its structure features a piperidine ring, along with aromatic rings and oxygen atoms, which all play a role in how it grabs serotonin receptors on cell surfaces. With a molar mass near 465 g/mol and a melting point sitting a bit above room temperature, cisapride ships well under standard pharmaceutical conditions. Its stability under normal humidity and temperature makes storing and dispensing it fairly straightforward for pharmacists.
Packaging calls for amber vials or light-resistant blisters, since prolonged light weakens the active ingredient over months. Labels tend to specify chemical name, salt form, dosage, batch number, expiry date, and storage advice. Each lot undergoes rigorous checks—purity, residual solvents, dissolution, and mass balance—before release. Tablets usually hold a binder, disintegrant, and a lubricant, keeping each dose consistent. Pharmacopoeias set out limits for impurities, so manufacturing sites follow every guideline, aiming for over 98% active compound per weight to meet international requirements.
Pharmacies once used straightforward synthesis steps, beginning with norephedrine derivatives and building up the core piperidine ring through cyclization. The process involves selective alkylation, halogen exchange, and coupling with benzamide intermediates. After versioning up prototypes, labs identified the right conditions for purity and yield. Reaction vessels, solvents, and temperature controls run tight: acidic or basic work-up followed, and crystals get filtered, dried, and milled into free-flowing powder or pressed into tablet blends. Analytical labs run chromatography and spectral analysis at every stage to avoid harmful byproducts.
Chemists in both academic and industrial spaces played with modifications, hoping for stronger or safer versions. Fluorinating aromatic rings, tweaking piperidine side chains, and shifting N-methyl groups became standard strategies. Some variants made it through early screening, but none matched cisapride’s gut-activating power without unwanted side effects. Research keeps stacking up on how these changes shift not just how fast the compound works, but also its risk—especially for heart rhythm safety, one of the key obstacles in future attempts.
Doctors and pharmacists listed cisapride under plenty of aliases according to country and manufacturer: Prepulsid in Canada, Propulsid in the United States, Cizolapide in Japan, and other local brandings. Scientific texts use synonyms like 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide. For import/export, global drug authorities track it by those synonyms and its CAS number to help customs and regulators check shipments.
Safety protocols developed quickly after cisapride’s launch. Within columns of pharmacy journals, practitioners started warning of the risk of heart rhythm problems, mainly QT interval prolongation visible on ECG readings. The risk climbs with other heart meds in the mix, as well as certain antibiotics and antifungals. Pharmacies and clinics switched to tighter screening: checking personal and family cardiac histories, running baseline ECGs, and reviewing all co-prescriptions for drug interactions. Storage and compounding guidelines focused on keeping children and untrained staff away from bulk powders, along with spill-kit training, gloves, and fume control where large volumes get dispensed.
Most use centred on gastroesophageal reflux disease unresponsive to standard care, diabetic gastroparesis, and functional dyspepsia in both adults and children. While proton pump inhibitors took center stage for acid suppression, nothing quite matched cisapride for nudging the gut muscles back to life. For some kids with severe esophageal reflux, cisapride made all the difference—until safety concerns hit the headlines and led to tighter prescription controls, or complete withdrawal where regulatory action demanded it.
Academic groups and pharma labs threw resources at not just improving gut selectivity but tackling the notorious heart side effects. Structure-activity relationship studies gave insight into which chemical tweaks worsened or eased the chance of arrhythmias. A community of gastroenterologists, cardiac specialists, and clinical pharmacists exchanged data across case reports, helping document reactions and red-flag scenarios more quickly than ever before. Some ongoing projects seek ways to block or offset the potassium channel inhibition at the root of cisapride’s cardiac risks, hoping to resurrect its benefits through safer analogs or counteractive secondary meds.
Major studies in rats and dogs set out toxicity curves well before the first patient doses. Those studies flagged thresholds where doses risked not just stomach symptoms, but irregular heartbeats and risk of sudden cardiac events. Surveillance in humans soon found that people with underlying heart conditions, or those on other QT-prolonging drugs, faced the greatest danger. By the late 1990s, spontaneous reports of arrhythmia and sudden death led to widespread warnings and market suspensions. The story reminds both developers and consumers that every therapeutic benefit comes tunable only within a window—push the dose, or mix in the wrong drug, and things can go from helpful to hazardous. Regulators worldwide keep adverse event databases open for more reports and push transparency in side effect tracking.
Cisapride’s withdrawal spurred a search for smarter, safer gut motility agents. The next wave of drug development borrows from its lessons, blending rigorous cardiac monitoring into every clinical trial. Some researchers investigate low-dose regimens or gut-selective release systems, trying to keep plasma concentrations below the danger zone. Molecular modeling and better screening allow teams to spot hERG channel blockers long before any candidate drug reaches the bedside. Machine learning tools now flag molecular features shared with cisapride, warning developers early in the process. Meanwhile, a motivated underground of clinicians share small-case experiences from compassionate use in cases without alternatives, raising hopes that with strict controls, cisapride or derivatives may one day return in targeted, safer forms for patients most in need.
Cisapride started off in hospitals and pharmacies as a tool against tough digestive troubles. Doctors reached for it to move food through the stomach more quickly. For folks with severe, chronic heartburn caused by gastroesophageal reflux disease (GERD), or for those struggling with slow stomach emptying, cisapride often seemed like the answer. The medication increases movement in the gut, which brings some relief to people whose stomachs drag their feet about sending food downward.
This drug quickly gained popularity in the 1990s, with many prescriptions written to soothe the discomfort and rising acid that make GERD miserable for millions. GERD isn’t just “bad heartburn” — it can wear down the lining of the esophagus, make swallowing painful, and even raise the risk for cancer if ignored. Some folks, myself included, remember those nights when acid wouldn’t let up, and the hope that a new treatment might bring a break from chronic pain.
Cisapride didn’t just speed up digestion. Its effects touched other parts of the body, especially the heart. Reports started trickling in about heart rhythm problems — dangerous ones. The drug sometimes triggered arrhythmias, and for a few patients, that risk turned into a life-or-death emergency. It wasn’t just one or two outliers, either. The FDA collected enough evidence to call for a new look at cisapride’s safety. For some, the relief cisapride offered came at too high a price.
Doctors and pharmacists had to weigh not only the benefits but also the significant risks. There’s a sense of trust between patients and providers — that what’s prescribed is as safe as possible. When that trust breaks after a scare like this, it echoes through the community, and everyone looks for better options.
Once the cardiac risks became clear, the drug left shelves in many places. In the U.S., health authorities and drug companies agreed it should only be available for very specific cases, most often in a controlled setting, not the local pharmacy. Other countries followed suit, and what had once been a promising answer for tough stomach problems quickly dropped out of mainstream use.
It’s a reminder that, in medicine, today’s hot new fix can have long-term consequences nobody expects. Cisapride helped pave the way for drugs with stronger safety records and taught researchers to look for side effects beyond just the target organ. Newer medicines tap into the lessons learned, aiming to help with chronic digestive troubles without kicking up additional health problems.
Millions still wrestle with GERD or slow stomachs. Treatment plans now rely more on lifestyle changes and prescribed acid reducers such as omeprazole or pantoprazole, which don’t share the same high risk for heart issues. Doctors get thorough with patient history, medications, and possible drug interactions, avoiding surprises whenever possible. My own experience — and what I’ve heard from friends — reinforces the importance of staying alert to any new symptoms and reporting them quickly.
The story of cisapride isn’t just about a single drug. It shows how quickly medicine adapts when real-world results don’t match early hopes and how teamwork between patients, doctors, and researchers shapes safer care. Cisapride did its job, but it also set a standard that today’s new treatments must meet and beat for the health of all.
Cisapride appeared with the promise of helping people manage serious stomach troubles. Some folks found relief from acid reflux and similar issues thanks to its ability to speed up how food moves through the digestive system. Even so, every medication comes with downsides. Cisapride’s side effects have sparked real concern among doctors, pharmacists, and families.
Many who took cisapride started to notice mild stomach cramps and diarrhea. More than a minor inconvenience, loose bowels can make daily routines tough to manage. I’ve seen how even low-level symptoms nudge patients to stop taking a drug or change their diet just to keep up with work or family life. Nausea struck some folks as well, along with an unsettled stomach or gas, making meals something to dread instead of enjoy.
Constipation can sneak up, too, leaving people frustrated as their body swings between extremes. Muscle pain and fatigue sometimes followed, though not as common, and left people feeling worn out.
Cisapride’s biggest danger lies in its effects on the heart. Some patients developed irregular heartbeats, a problem that doctors call arrhythmia. In my experience, heart rhythm changes never feel minor, especially for anyone with heart disease or anyone taking other meds affecting the heart.
The drug can lengthen the QT interval — an electrical measure doctors see on an ECG — increasing the chance of sudden, severe heart problems. According to published studies, the risk rose when people combined cisapride with other medicines or had liver conditions. QT prolongation sometimes led to torsades de pointes, a rare but life-threatening heart rhythm. Data from the FDA showed more than 340 cases of heart rhythm complications, including at least 80 deaths, before cisapride was pulled from the U.S. market.
The tough truth is that not everyone gets told about these possibilities. Time after time, clear conversations between doctors and patients make a difference. Doctors who explain both benefits and risks help families prepare. Checking liver health before starting cisapride, and keeping an eye on any other drugs a person takes, matters. I always ask about supplements and over-the-counter pills, since some can raise the number of side effects.
Patients also deserve careful follow-up. Medical teams catch trouble faster if patients know how to spot things like dizziness, missed heartbeats, or fainting. Early signs are sometimes brushed off, which makes outcomes worse.
Alternatives to cisapride have filled in some treatment gaps. Solutions like lifestyle changes, different prescription drugs, or guided physical therapy work for many with stomach disorders. The cisapride story reminds me how crucial real-world evidence is in medicine. Patients benefit from choices, not just promises, and honest reporting on risks gives everyone a stronger hand when it comes to their health.
In my work, clear conversations and shared decision-making have often meant fewer surprises down the road. Medicine should aim not only to fix discomfort, but to guard people against harm that comes from hidden risks.
Back in the 1990s, doctors often reached for Cisapride to help with stomach issues like severe heartburn and delayed gastric emptying. On paper, this drug looked like a simple fix. It worked by making the stomach muscles contract faster, pushing food along and reducing the discomfort millions felt daily. People found relief from symptoms that affected their quality of life. Life felt less complicated for those patients, myself included.
Relief sometimes hides a price. In those years, more and more medical reports started connecting Cisapride to a dangerous and unpredictable side effect: heart rhythm problems. Some people who took this medicine ended up with arrhythmias, a condition where the heart can lose its regular beat. For certain unlucky patients, these rhythm changes turned deadly. Pharmacovigilance studies confirmed that, especially in people already taking other medicines, the list of emergency room visits grew at an alarming rate.
The numbers forced medical regulators to take a closer look. A study from the FDA in the early 2000s listed more than 270 reports of serious irregular heartbeats linked to Cisapride, including over 80 deaths. Australia, Canada, the US, and much of Europe responded to these warnings. They imposed strict restrictions, took Cisapride off pharmacy shelves, or limited its use to tightly controlled programs. The risk of letting people continue to swallow this drug far outweighed the benefits, and I can remember families worried about friends who collapsed without warning.
Most people don’t expect medicine meant for heartburn to lead to funeral arrangements. Cisapride’s withdrawal hits home the lesson that the drug approval process can miss rare, devastating side effects during clinical trials, especially when thousands—or millions—begin to use the medicine all at once. Most trials don’t run long enough or with enough diverse people to catch every possible negative interaction.
For years, the routine answer was to blame patients for mixing medicines carelessly. Now, the conversation has shifted. Training for healthcare providers in drug interaction checks became a priority. Electronic prescribing systems that flag dangerous combinations play a much bigger role in offices and hospitals. Regulatory agencies learned to build stronger post-marketing surveillance and involve patients with real-world feedback. These steps build public trust, which matters when people are already hesitant about new therapies.
Researchers keep searching for solutions for stomach problems—drugs that repair digestive motility without risking the heartbeat. Doctors now rely on safer alternatives that have stood the test of time. Some individuals still work through the aftershocks, checking with their doctors before mixing any medications. My own experience has shaped a habit of asking questions and reading the insert for every bottle.
Cisapride’s story forces the public and regulators to face tough choices between solving symptoms and keeping people safe. Trust builds from open reporting, responsive systems, and companies showing that patient lives matter more than sales targets. The cost of getting it wrong leaves real scars on families and shakes faith in the medicines handed across drugstore counters.
Cisapride once turned heads for its promise in treating people with gastrointestinal conditions such as severe heartburn and delayed stomach emptying. The idea was simple: help food move along smoothly in the digestive tract, give relief to folks who felt weighed down after every meal. The drug works by boosting the action of acetylcholine, a chemical that speeds up natural stomach and intestine movement.
Unfortunately, for every benefit, there came some hidden dangers. Cisapride carries risks for serious heart rhythm problems, even life-threatening ones. Because of those risks, health authorities pulled Cisapride from most shelves after reports linked it to irregular heartbeats and sudden cardiac events. Doctors and pharmacists didn't take this lightly, and the FDA now allows the drug only under tightly-controlled circumstances. In countries where Cisapride remains on the market, strict use guidelines aren't optional—they matter as much as the drug itself.
With medications like Cisapride, a “just try a bit more” mindset doesn’t work. The dose depends on factors like age, weight, and which condition requires treatment. In my years of experience talking with patients on tricky meds, I’ve seen how a few milligrams too much can flip the script from relief to risk. Typical adult treatment starts at 5 to 10 mg taken fifteen to thirty minutes before meals, sometimes at bedtime, never on a hunch or by memory. Tinkering with the schedule without a doctor’s say-so lands patients in dangerous territory—dose increases or extra pills to “catch up” often trigger the harmful heart results authorities warned about.
Timing plays a bigger role than many patients understand. Absorption changes depending on when you eat, the kind of meal, and even other medicines in your routine. Grapefruit juice, certain antibiotics, antifungals, even some antidepressants can raise the level of Cisapride in your blood, bringing real danger. I’ve seen patients surprised to end up at the ER not because they ignored instructions, but because they didn't have all the information—another reason pharmacy and physician check-ins remain non-negotiable.
Safe dosing of Cisapride boils down to teamwork. Doctors rely on clear communication: full lists of everything you take, from daily vitamins to prescribed drugs. Electronic records open chances to catch dangerous combinations, but the best defense still comes from honest talk with both prescribers and pharmacists. Clinics with clear guidelines see fewer emergency visits and keep heart safety front and center. Patients who double-check each pill—especially for out-of-country or online orders—avoid mistakes that less-informed buyers fall into. I’ve sat with families who lost loved ones to “just one extra pill with dinner.” No good comes of keeping quiet about side effects or skipping appointments out of fear or cost.
No pill is harmless, but a culture of care and caution gives patients a shot at symptom relief without new threats around the corner. Encouraging each other to speak up, letting professionals do their job, and never treating prescriptions like supermarket choices—these steps save real lives. Cisapride has a role for some, but only with watchful eyes and learned hands guiding every step.
Cisapride draws a lot of attention in the medical field because it works by improving the movement of the stomach and intestines. For folks dealing with serious digestive issues like gastroparesis, this medication often becomes part of the conversation. Most people never hear about it until their doctor brings it up for stubborn stomach problems.
From my time working alongside clinicians, I often saw just how carefully they approached this drug. Cisapride manages to help some patients live more comfortably, but because of how it affects the heart, caution always takes the front seat. Right away, that means looking very closely at other medications on the list. That's not just a formality; ignoring it in the past led to tragedies that could have been avoided.
The heart rhythm issue, commonly called QT prolongation, makes cisapride notorious among healthcare workers. If something disrupts how cisapride gets broken down in the liver, the risk soars. Many medications rely on a group of enzymes, mainly CYP3A4, to help clear them out. Cisapride sticks around longer if this cleaning crew gets blocked, turning a helpful medicine into something outright dangerous.
Medications like certain antibiotics (clarithromycin, erythromycin), antifungals (ketoconazole, itraconazole), or HIV protease inhibitors can block these enzymes. Combining these with cisapride raises the drug's levels in the blood and gives the heart more trouble than it can handle. Even common antidepressants have landed on warning lists because they can tip the balance.
Not long ago, I remember a patient who started an over-the-counter herbal supplement after years on a stable regimen with cisapride. The supplement contained St. John’s Wort, which, instead of slowing the drug’s breakdown, made it too fast. Medicines don’t work as well that way and symptom control fell apart. On the other end, grapefruit juice—something people don’t always mention to their doctors—can block the same enzymes, leading to dangerous drug buildup.
Looking at the published evidence, the stories stack up. The FDA ended up heavily restricting cisapride because heart arrhythmia deaths could have been prevented with better checks. Unchecked polypharmacy—the use of many drugs by the same person—turned what should have been routine symptom relief into an emergency room visit.
Checking every medication, over-the-counter pill, vitamin, or supplement before writing a prescription doesn’t just look good on paper. Lives depend on it. Good systems in hospitals flag risky combinations right away, but most folks fill some or all of their medications at different pharmacies, and that weakens the safety net. Electronic health records help but they don't catch everything. Open conversations—where patients mention every single thing they take, even the so-called “natural” remedies—make a bigger difference than many realize.
From a practical perspective, reviewing every change with a pharmacist or doctor makes sense, even for something that seems minor. Every prescriber worth their salt checks for enzyme blockers or inducers, but reminders still help. A clear medication list, shared with everyone involved, serves everyone well, from patients to the most experienced specialists.
Staying alert helps keep cisapride from turning risky. The lessons learned echo far outside of one medication, setting a stronger standard for how we approach drug interactions and patient safety.
| Names | |
| Preferred IUPAC name | 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2-methoxybenzamide |
| Other names |
Propulsid Cisaprid Renzapride |
| Pronunciation | /ˈsɪs.ə.praɪd/ |
| Identifiers | |
| CAS Number | 81098-60-4 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Cisapride**: ``` CCN(CC)CCOC1=CC=CC=C1CNC(=O)NC2=CC=CC=C2OC ``` This is the SMILES (Simplified Molecular Input Line Entry System) string used for rendering the 3D model of cisapride in JSmol or similar molecular viewers. |
| Beilstein Reference | 1721392 |
| ChEBI | CHEBI:3609 |
| ChEMBL | CHEMBL132 |
| ChemSpider | 2098 |
| DrugBank | DB00604 |
| ECHA InfoCard | 100.064.661 |
| EC Number | EC 3.1.1.7 |
| Gmelin Reference | 87853 |
| KEGG | D07710 |
| MeSH | D015663 |
| PubChem CID | 2718 |
| RTECS number | GF8350000 |
| UNII | JWZ2768TF2 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C23H29ClN3O4 |
| Molar mass | 465.96 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.6 |
| Vapor pressure | 0.0000277 mmHg |
| Acidity (pKa) | 13.11 |
| Basicity (pKb) | 7.94 |
| Magnetic susceptibility (χ) | -7.8×10^-6 cm³/mol |
| Refractive index (nD) | 1.603 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.46 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 410.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -302.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5866 kJ/mol |
| Pharmacology | |
| ATC code | A03FA02 |
| Hazards | |
| Main hazards | Cardiac arrhythmias (QT prolongation, ventricular tachycardia, torsades de pointes) |
| GHS labelling | GHS02, GHS07 |
| Pictograms | Tablet |
| Signal word | Warning |
| Hazard statements | Hazard statements: H301, H315, H319, H335 |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 2-3-0 |
| Flash point | 100 °C |
| Autoignition temperature | 280 °C |
| Lethal dose or concentration | LD50 (oral, rat): 840 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 = 510 mg/kg |
| NIOSH | NQ9600000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.1 mg/kg every 8-12 hours |
| IDLH (Immediate danger) | IDLH: Not Listed |
| Related compounds | |
| Related compounds |
Prucalopride Mosapride Metoclopramide Tegaserod Renzapride |
